Friedberg Group Amends Stake in VaccinEx, Inc.

Ticker: VCNX · Form: SC 13D/A · Filed: Aug 7, 2024 · CIK: 1205922

Vaccinex, Inc. SC 13D/A Filing Summary
FieldDetail
CompanyVaccinex, Inc. (VCNX)
Form TypeSC 13D/A
Filed DateAug 7, 2024
Risk Levelmedium
Pages8
Reading Time10 min
Key Dollar Amounts$0.0001, $5.10, $7
Sentimentneutral

Sentiment: neutral

Topics: ownership-change, amendment, sec-filing

Related Tickers: VACC

TL;DR

Friedberg group filed an amendment on their VaccinEx stake. Watch for more details.

AI Summary

On August 7, 2024, Albert D. Friedberg and associated entities, including Friedberg Global-Macro Hedge Fund Ltd., filed an amendment (No. 11) to their Schedule 13D regarding VaccinEx, Inc. The filing indicates a change in beneficial ownership, though specific new holdings or changes in percentage are not detailed in this excerpt. The filing was made under the Securities Exchange Act of 1934.

Why It Matters

This amendment signals a potential shift in the ownership structure or strategy of VaccinEx, Inc., which could impact its stock performance and future corporate actions.

Risk Assessment

Risk Level: medium — Schedule 13D filings, especially amendments, often precede significant corporate events or changes in control, introducing uncertainty.

Key Numbers

  • 11 — Amendment Number (Indicates this is the eleventh update to the filing.)

Key Players & Entities

  • Albert D. Friedberg (person) — Filing party
  • Friedberg Global-Macro Hedge Fund Ltd. (company) — Filing party
  • Friedberg Mercantile Group Ltd. (company) — Filing party
  • Pan Atlantic Holdings Ltd. (company) — Filing party
  • VaccinEx, Inc. (company) — Subject company
  • Thomas J. Rice (person) — Authorized representative
  • Baker & McKenzie LLP (company) — Legal counsel

FAQ

What specific changes in beneficial ownership are reported in this amendment?

This excerpt does not detail the specific changes in beneficial ownership, only that an amendment was filed.

What is the CUSIP number for VaccinEx, Inc. common stock?

The CUSIP number for VaccinEx, Inc. common stock is 918640 202.

Who is the subject company of this Schedule 13D filing?

The subject company is VaccinEx, Inc.

What is the primary business of VaccinEx, Inc. according to the filing?

VaccinEx, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).

When was this amendment filed with the SEC?

This amendment was filed on August 7, 2024.

Filing Stats: 2,405 words · 10 min read · ~8 pages · Grade level 7.8 · Accepted 2024-08-07 16:10:55

Key Financial Figures

  • $0.0001 — me of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securiti
  • $5.10 — ple transactions at prices ranging from $5.10 to $7.40, inclusive. 9 Signatures
  • $7 — actions at prices ranging from $5.10 to $7.40, inclusive. 9 Signatures After

Filing Documents

of the Statement is hereby amended by the addition of the following information

Item 3 of the Statement is hereby amended by the addition of the following information: On August 5, 2024, FCMI Parent and Mr. Friedberg acquired beneficial ownership of 3,653 shares of Common Stock through the following open-market purchases made by FCMI Parent: Number of shares purchased Price per share ($) Amount paid ($) 3,653 4.60 16,803.80 On August 6, 2024, FCMI Parent and Mr. Friedberg acquired beneficial ownership of 2,753 shares of Common Stock through the following open-market purchases made by FCMI Parent: Number of shares purchased Price per share ($) Amount paid ($) 2,753 4.92 13,544.76 Item4. Purpose of Transaction.

of the Statement is hereby amended by the addition of the following information

Item 4 of the Statement is hereby amended by the addition of the following information: The aggregate total of 6,406 shares of Common Stock described in Item 3 were purchased by FCMI Parent for investment purposes. The information provided in

with respect to the 6,406 shares of Common Stock purchased is incorporated by reference herein

Item 3 with respect to the 6,406 shares of Common Stock purchased is incorporated by reference herein. The Filing Persons do not have any present intention or arrangements to acquire additional shares of Common Stock. The Filing Persons do not have any present intention to sell any Common Stock that will be included in such Registration Statement, and note that their ability to effect dispositions of Common Stock, other than pursuant to the Registration Statement, or prior shelf registration statements filed by the Company, may be limited by their status as affiliates of the Issuer. deem appropriate. Except as described herein, the Filing Persons do not have any plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D. The Filing Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto. Item5. Interest in Securities of the Issuer. The table in Item 5 of the Statement showing beneficial ownership of the Issuers Common Stock by each of the Filing Persons, together with the introductory paragraph to such table and the paragraph immediately following such table, as well as the information regarding ownership of the Issuers Common Stock by the directors and officers of the Filing Persons, are hereby amended and restated in their entirety as follows: On the date of this Schedule 13D (Amendment No. 11), the Filing Persons are the beneficial owners of a total of 799,522 shares of the Issuers Common Stock, representing 46.3% of the Issuers outstanding Common Stock. Each Filing Persons direct ownership and beneficial ownership has been computed as a percentage of 1,727,700 shares outstand

Signatures

Signatures After reasonable inquiry and to the best of each of the undersigneds knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct. Dated: August 7, 2024 FCMI PARENT CO. By: /s/ Dan Scheiner Name: Dan Scheiner Title: Vice President PAN ATLANTIC HOLDINGS LTD. By: /s/ Mary Ellen Bourque Name: Mary Ellen Bourque Title: Director FRIEDBERG GLOBAL-MACRO HEDGE FUND LTD. By: /s/ Albert D. Friedberg Name: Albert D. Friedberg Title: Director FRIEDBERG MERCANTILE GROUP LTD. By: /s/ Albert D. Friedberg Name: Albert D. Friedberg Title: Director ALBERT D. FRIEDBERG, individually /s/ Albert D. Friedberg Name: Albert D. Friedberg 10

View Full Filing

View this SC 13D/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.